Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Randomised, Placebo-controlled Multicentre Phase III Clinical Study Followed by Open-label Phase on the Efficacy and Tolerability of Budesonide 3 mg Effervescent Tablet in Patients With Resistant Oral Chronic GvHD

NCT00887263 is registered in ClinicalTrials.gov with Dr. Falk Pharma GmbH as lead sponsor.

NCT NCT00887263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00887263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Randomised, Placebo-controlled Multicentre Phase III Clinical Study Followed by Open-label Phase on the Efficacy and Tolerability of Budesonide 3 mg Effervescent Tablet in Patients With Resistant Oral Chronic GvHD
Lead sponsor
Dr. Falk Pharma GmbH
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2009
Completion date
October 31, 2015
Enrollment
186 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

oral chronic graft vs host disease